Task Force #1 - Magnitude of the prevention problem: Opportunities and challenges

Journal of the American College of Cardiology

Volumn 40, Issue 4, 2002, Pages 588-603

  Benjamin, Emelia J ^a   Smith Jr , Sidney C ^a   Cooper, Richard S ^a   Hill, Martha N ^a   Luepker, Russell V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; CARDIOLOGY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; DIABETES MELLITUS; HEALTH CARE POLICY; HUMAN; OBESITY; PRIORITY JOURNAL; SMOKING CESSATION;

CARDIOVASCULAR DISEASES; ETHNIC GROUPS; FEMALE; HEALTH PROMOTION; HUMANS; MALE; PRACTICE GUIDELINES; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 0037151647     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02082-X     Document Type: Conference Paper

References (135)

1. The global burden of disease in 1990
2. Primary prevention of coronary heart disease
3. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: Demographic, physical, dietary and biochemical characteristics
4. Prediction and possible prevention of coronary disease
5. Social/economic status and disease
6. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on cardiovascular disease prevention
7. Social inequality, ethnicity and cardiovascular disease
8. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on cardiovascular disease prevention
9. Neighborhood of residence and incidence of coronary heart disease
10. Epidemiology of atherosclerotic disease in population groups
11. Recent trends in acute coronary heart disease - Mortality, morbidity, medical care, and risk factors
12. Cardiovascular risk factor change - 1973-74 to 1980-82: The Minnesota Heart Survey
13. Mechanisms precipitating acute cardiac events: Review and recommendations of an NHLBI workshop. National Heart, Lung, and Blood Institute. Mechanisms precipitating acute cardiac events participants
14. Estimation of contribution of changes in classic risk factors to trends in coronary event rates across the WHO MONICA Project populations
15. Risk factors for coronary heart disease among older men and women: A prospective study of community-dwelling elderly
16. Coronary risk factors in the octogenarian: Is control important?
17. Deaths: Preliminary data for 2000
18. Trends in serum cholesterol levels, 1980-1997
19. Trends in blood pressure control and stroke in a metropolitan area: The Minnesota Heart Study
20. Surveillance for selected tobacco-use behaviors - United States, 1900-1994
21. Ethnic and socioeconomic differences in cardiovascular disease risk factors: Findings for women from the Third National Health and Nutrition Examination Survey, 1988-1994
22. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult U.S. population. Data from the health examination surveys, 1960 to 1991
23. Declining serum total cholesterol levels among U.S. adults
24. Prevalence of hypertension in the U.S. adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991
25. Secular trends in blood pressure levels in Denmark 1964-1991
26. Physical activity trends - United States, 1990-1998
27. Overweight and obesity in the United States: Prevalence and trends, 1960-1994
28. Diabetes and cardiovascular disease. The Framingham study
29. Impact of high-normal blood pressure on the risk of cardiovascular disease
30. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: Findings for 5 large cohorts of young adult and middle-aged men and women
31. Primary prevention of coronary heart disease in women through diet and lifestyle
32. Optimal risk factors in the population: Prognosis, prevalence, and secular trends; data from Goteborg population studies
33. Cardiovascular mortality in hypertensive men according to presence of associated risk factors
34. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet
35. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women
36. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
37. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
38. Cardiovascular health in childhood: A statement for healthcare professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young of the American Heart Association
39. A randomized trial of sodium intake and blood pressure in newborn infants
40. Long-term effects of neonatal sodium restriction on blood pressure
41. Interventions for preventing obesity in children
42. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction
43. AHA conference proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Executive summary
44. Cardiovascular protection and blood pressure reduction: A meta-analysis
45. Effect of HMG-CoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials
46. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
47. Physical fitness and activity as separate heart disease risk factors: A meta-analysis
48. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51)
49. Lifetime health and economic benefits of weight loss among obese persons
50. A clinical practice guideline for treating tobacco use and dependence: A US public health service report
51. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization
52. 27th Bethesda conference: Matching the intensity of risk factor management with the hazard for coronary disease events
53. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
54. Clustering of metabolic factors and coronary heart disease
55. Mortality from coronary heart disease in subjects with type 2 diabetes and in don-diabetic subjects with and without prior myocardial infarction
56. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
57. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
58. Preventing heart attack and death in patients with coronary disease
59. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction
60. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 Update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
61. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
62. Exercise-based rehabilitation for coronary heart disease
63. Risk-reduction therapy: The challenge to change
64. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project
65. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease
66. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3
67. Ineffective secondary prevention in survivors of cardiovascular events in the U.S. population: Report from the Third National Health and Nutrition Examination Survey
68. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3
69. National Survey on Gender Differences in Cardiac Rehabilitation Programs. Patient characteristics and enrollment patterns
70. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP)
71. Improving the quality of care for Medicare patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project
72. Health and economic benefits of increased beta-blocker use following myocardial infarction
73. Cost effectiveness of ramipril treatment for cardiovascular risk reduction
74. Multiple risk factor interventions for primary prevention of coronary heart disease
75. Decline in mortality from coronary heart disease in Finland from 1969 to 1979
76. Joint analysis of three U.S. community intervention trials for reduction of cardiovascular disease risk
77. Community education for cardiovascular disease prevention. Morbidity and mortality results from the Minnesota Heart Health Program
78. Effects of community-wide education on cardiovascular disease risk factors
79. Effects of a community-wide health education program on cardiovascular disease morbidity and mortality: The Stanford Five-City Project
80. Community education for cardiovascular disease prevention: Risk factor changes in the Minnesota Heart Health Program
81. The Pawtucket Heart Health Program: Community changes in cardiovascular risk factors and projected disease risk
82. Community health survey in an urban African-American neighborhood: Distribution and correlates of elevated blood pressure
83. Prevalence and social correlates of cardiovascular disease risk factors in Harlem
84. Linking community-based blood pressure measurement to clinical care: A randomized controlled trial of outreach and tracking by community health workers
85. A clinic and community-based approach to hypertension control for an underserved minority population: Design and methods
86. The determinants of hypertension awareness, treatment, and control in an insured population
87. Barriers to blood pressure control
88. Review of community-based research: Assessing partnership approaches to improve public health
89. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure
90. The effect of patient race and socio-economic status on physicians' perceptions of patients
91. Behavior and biology: The basic sciences for AHA action: Presented at the 70th scientific sessions of the American Heart Association, November 9, 1997, Orlando, Florida
92. Barriers to hypertension care and control
93. Inadequate management of blood pressure in a hypertensive population
94. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. European action on secondary prevention by intervention to reduce events
95. Why don't physicians follow clinical practice guidelines? A framework for improvement
96. The therapeutic gap - Compliance with medication and guidelines
97. Lifestyle changes after a myocardial infarction
98. Adherence to health messages: A social psychological perspective
99. Integrated approaches to management of hypertension: Promoting treatment acceptance
100. Overcoming barriers to preventive care
101. Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke
102. Canadian physicians' attitudes about and preferences regarding clinical practice guidelines
103. Practice guidelines developed by specialty societies: The need for a critical appraisal
104. Self-reported hypertension treatment practices among primary care physicians: Blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine
105. The essence of effective treatment and compliance is simplicity
106. Indications for cholesterol-lowering medication: Comparison of risk-assessment methods
107. The management of hypertension in Canada: A review of current guidelines, their shortcomings and implications for the future
108. Guidelines on preventing cardiovascular disease in clinical practice
109. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative
110. Communication skills for preventive interventions
111. The multilevel compliance challenge: Recommendations for a call to action. A statement for healthcare professionals
112. Impact of medication nonadherence on coronary heart disease outcomes. A critical review
113. A critical review of interventions to increase compliance with medication-taking, obtaining medication refills, and appointment-keeping in the treatment of cardiovascular disease
114. Prediction of coronary heart disease using risk factor categories
115. Guidelines for clinical guidelines
116. A simple computer program for guiding management of cardiovascular risk factors and prescribing
117. A means to an end: An overview of a hyperlipidemia outcomes management program
118. Put prevention into practice. Evaluation of program initiation in nine Texas clinical sites
119. Improving patient outcomes by pooling resources (the Texas Heart Care Partnership experience)
120. Heart disease education and prevention program targeting immigrant Latinos: Using focus group responses to develop effective interventions
121. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: A systematic review
122. Critical pathways: A review
123. Team management of patients with heart failure: A statement for healthcare professionals from the Cardiovascular Nursing Council of the American Heart Association
124. Organizational interventions to encourage guideline implementation
125. Which is more important for the efficiency of hypertension treatment: Hypertension stage, type of drug or therapeutic compliance?
126. Social marketing: Application to medical education